Eunice Wang, MD, discusses the potential impact of menin inhibitors on the treatment of acute myeloid leukemia.
Eunice Wang, MD, the chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, discusses the potential impact of menin inhibitors on the treatment of acute myeloid leukemia (AML).
Menin inhibitors potentially represent the next forefront of targeted treatment for patients with AML, according to Wang. Previously, positive results have been observed with other targeted therapies, such as the CD33-targeting antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg), FLT3 inhibitors midostaurin (Rydapt) and gilteritinib (Xospata), and IDH inhibitors ivosidenib (Tibsovo) and enasidenib (Idhifa), Wang says. Most recently, older patients with AML have also been found to benefit from a BCL2-targeted treatment approach, Wang notes.
As such, menin inhibitors show potential as a treatment option for patients with NPM1 and KM22 rearrangements, Wang adds. Additionally, menin inhibitors could be combined with other targeted treatment options to further enhance outcomes, Wang concludes.